Literature DB >> 21766818

Engineering a synthetic ligand for tumor necrosis factor-alpha.

Nidhi Gupta1, Paul E Belcher, Stephen Albert Johnston, Chris W Diehnelt.   

Abstract

One approach to prepare protein binding ligands is to join two low-affinity ligands that bind different sites on the target protein to create a high-affinity bivalent ligand. This typically requires some knowledge of the ligand binding site and requires exquisite orientation of the ligands in order to achieve maximum binding affinity. Here, we explored the limit of affinity improvement possible with no a priori knowledge of peptide binding site and with minimal effort spent in linking the lead peptides. We compared the affinity enhancement from linking two peptides with low affinity for tumor necrosis factor-α (TNFA) to the affinity enhancement from linking affinity improved versions of these peptides using several different scaffolds. We found that we achieved the highest affinity gain not by the precise positioning of the peptides, but rather by using affinity improved versions of the lead peptides to produce synbodies with apparent K(D)'s of 9 to 48 nM. Kinetic analysis showed that the binding kinetics of the synbody are strongly influenced by the kinetics of the starting peptide. This suggests that careful selection of peptides based on their kinetic profile prior to linking will influence the kinetics of the final binding agent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766818     DOI: 10.1021/bc200091c

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  2 in total

1.  A technology for developing synbodies with antibacterial activity.

Authors:  Valeriy Domenyuk; Andrey Loskutov; Stephen Albert Johnston; Chris W Diehnelt
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

2.  A Simple Platform for the Rapid Development of Antimicrobials.

Authors:  Stephen Albert Johnston; Valeriy Domenyuk; Nidhi Gupta; Milene Tavares Batista; John C Lainson; Zhan-Gong Zhao; Joel F Lusk; Andrey Loskutov; Zbigniew Cichacz; Phillip Stafford; Joseph Barten Legutki; Chris W Diehnelt
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.